|8.95||-0.7400||-7.64%||Vol 1.03M||1Y Perf -15.89%|
|Aug 9th, 2022 16:00 DELAYED|
|- -||0.10 1.12%|
|Target Price||16.57||Analyst Rating||Strong Buy 1.43|
|Potential %||85.14||Finscreener Ranking||★+ 43.69|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 38.90|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||+ 33.05|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||41.91||Earnings Rating||Strong Buy|
|Market Cap||502.04M||Earnings Date||2nd Aug 2022|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.28|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.09M|
|Avg. Monthly Volume||596.42K|
|Avg. Quarterly Volume||574.94K|
Evolus Inc. (NASDAQ: EOLS) stock closed at 9.69 per share at the end of the most recent trading day (a 3.09% change compared to the prior day closing price) with a volume of 650.57K shares and market capitalization of 502.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 125 people. Evolus Inc. CEO is David Moatazedi.
The one-year performance of Evolus Inc. stock is -15.89%, while year-to-date (YTD) performance is 48.85%. EOLS stock has a five-year performance of %. Its 52-week range is between 5.061 and 14.34, which gives EOLS stock a 52-week price range ratio of 41.91%
Evolus Inc. currently has a PE ratio of -9.80, a price-to-book (PB) ratio of 10.68, a price-to-sale (PS) ratio of 7.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.26%, a ROC of -73.05% and a ROE of -158.25%. The company’s profit margin is -57.26%, its EBITDA margin is -51.60%, and its revenue ttm is $95.24 Million , which makes it $1.70 revenue per share.
Of the last four earnings reports from Evolus Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Evolus Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Evolus Inc. is Strong Buy (1.43), with a target price of $16.57, which is +85.14% compared to the current price. The earnings rating for Evolus Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evolus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evolus Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 47.39, ATR14 : 1.07, CCI20 : -144.02, Chaikin Money Flow : -0.19, MACD : -0.69, Money Flow Index : 39.32, ROC : -29.37, RSI : 20.00, STOCH (14,3) : 9.98, STOCH RSI : 0.31, UO : 35.70, Williams %R : -90.02), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evolus Inc. in the last 12-months were: Crystal Muilenburg (Sold 11 857 shares of value $123 110 ), David Moatazedi (Sold 211 605 shares of value $2 445 178 ), David N. Gill (Sold 10 313 shares of value $137 664 ), Lauren P. Silvernail (Sold 92 689 shares of value $1 130 276 ), Rui Avelar (Sold 24 485 shares of value $258 910 ), Vikram Malik (Sold 93 160 shares of value $971 283 )
Tue, 02 Aug 2022 13:05 GMT Mizuho Securities Believes Evolus (EOLS) Still Has Room to Grow- TipRanks. All rights reserved.
Wed, 11 May 2022 02:25 GMT Evolus (EOLS) Gets a Buy Rating from Mizuho Securities- TipRanks. All rights reserved.
Wed, 09 Mar 2022 07:29 GMT Evolus Updates 1 Key Risk Factor- TipRanks. All rights reserved.
Tue, 08 Feb 2022 09:18 GMT Evolus (EOLS) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.